Palo Alto Networks Scoops Up Smaller Players, Smack Talks Competition
The cybersecurity name fired off some punches at the competition and picked up another bolt-on acquisition amid earnings.
Palo Alto Networks Surges, but Its Close Is More Important
Shares of the provider of network security platforms could bump into a resistance zone after a strong start.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Broader Market Drags Affecting Salesforce Could Drive Buying Opportunity
CRM shouldn't be sagging with the broader tech sector.
VMware Stock: Screaming Buy or Screaming 'Death Cross'?
I see VMW trading in the high $130s and my engine gets running.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Salesforce Stock Surges as Cloud King Status Is Cemented
Salesforce is characteristically sustaining strength despite a heap of headwinds.